Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Walter Reed Army Institute of Research/US Army Medical Research Directorate-Africa, Nairobi, Kenya.
Clin Infect Dis. 2020 Jul 27;71(3):652-660. doi: 10.1093/cid/ciz877.
Patients living with human immunodeficiency virus (PLWH) with low CD4 counts are at high risk for immune reconstitution inflammatory syndrome (IRIS) and death at antiretroviral therapy (ART) initiation.
We investigated the clinical impact of IRIS in PLWH and CD4 counts <100 cells/μL starting ART in an international, prospective study in the United States, Thailand, and Kenya. An independent review committee adjudicated IRIS events. We assessed associations between baseline biomarkers, IRIS, immune recovery at week 48, and death by week 48 with Cox models.
We enrolled 506 participants (39.3% were women). Median age was 37 years, and CD4 count was 29 cells/μL. Within 6 months of ART, 97 (19.2%) participants developed IRIS and 31 (6.5%) died. Participants with lower hemoglobin at baseline were at higher IRIS risk (hazard ratio [HR], 1.2; P = .004). IRIS was independently associated with increased risk of death after adjustment for known risk factors (HR, 3.2; P = .031). Being female (P = .004) and having a lower body mass index (BMI; P = .003), higher white blood cell count (P = .005), and higher D-dimer levels (P = .044) were also significantly associated with increased risk of death. Decision-tree analysis identified hemoglobin <8.5 g/dL as predictive of IRIS and C-reactive protein (CRP) >106 μg/mL and BMI <15.6 kg/m2 as predictive of death.
For PLWH with severe immunosuppression initiating ART, baseline low BMI and hemoglobin and high CRP and D-dimer levels may be clinically useful predictors of IRIS and death risk.
开始抗逆转录病毒治疗(ART)时 CD4 计数较低的人类免疫缺陷病毒(HIV)感染者(PLWH)存在免疫重建炎症综合征(IRIS)和死亡的高风险。
我们在美国、泰国和肯尼亚进行了一项国际性、前瞻性研究,调查了开始 ART 时 CD4 计数<100 个/μL 的 PLWH 中 IRIS 的临床影响。一个独立的审查委员会裁定了 IRIS 事件。我们使用 Cox 模型评估了基线生物标志物、IRIS、第 48 周的免疫恢复和第 48 周的死亡之间的关联。
我们纳入了 506 名参与者(39.3%为女性)。中位年龄为 37 岁,CD4 计数为 29 个/μL。在 ART 开始后 6 个月内,97 名(19.2%)参与者发生了 IRIS,31 名(6.5%)死亡。基线时血红蛋白较低的参与者发生 IRIS 的风险更高(风险比 [HR],1.2;P =.004)。在调整了已知危险因素后,IRIS 与死亡风险增加独立相关(HR,3.2;P =.031)。女性(P =.004)和较低的体重指数(BMI;P =.003)、较高的白细胞计数(P =.005)和较高的 D-二聚体水平(P =.044)也与死亡风险增加显著相关。决策树分析确定血红蛋白<8.5 g/dL 预测 IRIS,C 反应蛋白(CRP)>106 μg/mL 和 BMI<15.6 kg/m2 预测死亡。
对于开始 ART 时严重免疫抑制的 PLWH,基线时低 BMI 和血红蛋白以及高 CRP 和 D-二聚体水平可能是预测 IRIS 和死亡风险的有用临床指标。